Innoviva Stock Price, News & Analysis

Innoviva, Inc. (NASDAQ: INVA) is a diversified healthcare holding company with a focus on pharmaceutical preparation manufacturing and commercial-stage therapeutics. According to company disclosures, Innoviva combines a core royalties portfolio, a critical care and infectious disease platform operated through Innoviva Specialty Therapeutics, and a portfolio of strategic investments in healthcare assets. The company’s common stock is listed on the NASDAQ Global Select Market under the symbol INVA.

Innoviva’s royalties portfolio centers on respiratory assets partnered with Glaxo Group Limited (GSK). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. These royalty streams provide an ongoing revenue source that complements Innoviva’s operating businesses and investment activities.

Innoviva Specialty Therapeutics: Critical Care and Infectious Disease

Through its subsidiary Innoviva Specialty Therapeutics (IST), Innoviva is active in the development and commercialization of therapies for serious infections and critical care conditions. IST’s commercial portfolio, as described in company news releases, includes multiple FDA-approved medicines:

• GIAPREZA® (angiotensin II), through the La Jolla Pharmaceutical Company affiliate, approved to increase blood pressure in adults with septic or other distributive shock.
• XERAVA® (eravacycline), through La Jolla, approved for the treatment of complicated intra-abdominal infections in adults.
• XACDURO® (sulbactam for injection; durlobactam for injection), through Entasis Therapeutics Inc., co-packaged for intravenous use and approved for adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex.
• ZEVTERA® (ceftobiprole medocaril sodium for injection), an advanced-generation cephalosporin antibiotic approved in the U.S. for adult patients with Staphylococcus aureus bloodstream infections (bacteremia), including right-sided infective endocarditis, adult patients with acute bacterial skin and skin structure infections (ABSSSI), and adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP).

IST also develops and presents clinical, pharmacokinetic-pharmacodynamic, and microbiologic data across this portfolio, reflecting a focus on serious bacterial infections, drug-resistant pathogens, and critical care settings.

Zoliflodacin / NUZOLVENCE® and Gonorrhea Treatment

A key asset associated with Innoviva’s infectious disease platform is zoliflodacin, a first-in-class, single-dose, oral antibiotic from the spiropyrimidinetrione class. It has been developed as a treatment for uncomplicated urogenital gonorrhea, including infections caused by strains resistant to current first-line therapies. In collaboration with the Global Antibiotic Research & Development Partnership (GARDP), Innoviva Specialty Therapeutics supported a pivotal Phase 3, multinational, randomized, controlled trial that demonstrated non-inferiority of a single 3 g oral dose of zoliflodacin compared to ceftriaxone plus azithromycin in uncomplicated urogenital gonorrhea.

Innoviva reports that the U.S. Food and Drug Administration (FDA) granted zoliflodacin Qualified Infectious Disease Product (QIDP) designation, allowing Priority Review and extended market exclusivity. Subsequent disclosures describe FDA acceptance of a New Drug Application and assignment of a Prescription Drug User Fee Act (PDUFA) target action date. In later communications, Innoviva Specialty Therapeutics announced FDA approval of NUZOLVENCE® (zoliflodacin) for oral suspension as a first-in-class, single-dose oral medication for adults and pediatric patients 12 years and older weighing at least 35 kg with uncomplicated urogenital gonorrhea.

NUZOLVENCE is described as a bacterial type II topoisomerase inhibitor with a mechanism of action distinct from currently approved antibiotics and with demonstrated activity against drug-resistant Neisseria gonorrhoeae. Company materials also summarize key safety information, including contraindications, embryo-fetal toxicity warnings, potential testicular toxicity and fertility risks based on animal data, hypersensitivity reactions, Clostridioides difficile infection risk, and common adverse reactions such as headache, dizziness, nausea, and diarrhea.

Therapeutic Focus and Disease Areas

Across its specialty therapeutics platform, Innoviva concentrates on serious infectious diseases and critical care indications. Its marketed and pipeline assets address:

• Drug-resistant gram-negative infections, including HABP/VABP due to susceptible Acinetobacter baumannii-calcoaceticus complex (XACDURO).
• Gram-positive infections such as MRSA-related Staphylococcus aureus bacteremia, ABSSSI, and CABP (ZEVTERA).
• Complicated intra-abdominal infections in adults (XERAVA).
• Hemodynamic support in septic or other distributive shock (GIAPREZA).
• Sexually transmitted infections, specifically uncomplicated gonorrhea, including drug-resistant strains (zoliflodacin/NUZOLVENCE).

Innoviva Specialty Therapeutics frequently presents clinical and pharmacologic data at major infectious disease meetings such as IDWeek, highlighting subgroup analyses, microbiologic surveillance, and PK-PD modeling for agents like zoliflodacin, ceftobiprole, sulbactam-durlobactam, and eravacycline.

Strategic Investments and Capital Allocation

Beyond royalties and marketed products, Innoviva maintains a portfolio of strategic healthcare investments held through various subsidiaries. Company reports reference investments in organizations developing therapies and technologies in areas such as infectious disease and neurotechnology. Innoviva also discloses activities such as term loans to development-stage companies and equity investments in private and public healthcare businesses.

Innoviva’s financial communications describe the company’s use of capital for share repurchase programs, debt management, and acquisitions of therapeutic assets and platforms, such as the acquisition of a long-acting oral drug delivery platform and related assets from Lyndra Therapeutics, Inc. These activities are presented as part of a broader capital allocation approach within its diversified holding company structure.

Stock Listing, Sector, and Regulatory Reporting

Innoviva’s common stock trades on the NASDAQ Global Select Market under the ticker INVA. The company is classified in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector. Innoviva files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including Form 8-K filings that furnish quarterly earnings press releases and other material information.

FAQs about Innoviva, Inc. (INVA)

• What does Innoviva, Inc. do?
  

  Innoviva is a diversified healthcare holding company with three main components: a royalties portfolio linked to respiratory products partnered with GSK, a critical care and infectious disease platform operated through Innoviva Specialty Therapeutics, and a portfolio of strategic investments in healthcare assets.

• How does Innoviva generate revenue?
  

  According to its public disclosures, Innoviva generates revenue from net royalties on GSK respiratory products such as RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, from net product sales of therapies marketed through Innoviva Specialty Therapeutics, and from license and other revenue associated with its assets and partnerships.

• What is Innoviva Specialty Therapeutics (IST)?
  

  Innoviva Specialty Therapeutics is a subsidiary of Innoviva focused on therapies for critical care and infectious disease. Through affiliates such as La Jolla Pharmaceutical Company and Entasis Therapeutics Inc., IST markets products including GIAPREZA, XERAVA, XACDURO, and ZEVTERA, and advances pipeline assets such as zoliflodacin/NUZOLVENCE.

• Which infectious diseases are targeted by Innoviva’s products?
  

  Company materials indicate that Innoviva’s portfolio addresses hospital-acquired and ventilator-associated bacterial pneumonia due to susceptible Acinetobacter (XACDURO), MRSA and MSSA bloodstream infections and other serious bacterial infections (ZEVTERA), complicated intra-abdominal infections (XERAVA), and uncomplicated urogenital gonorrhea, including drug-resistant strains (zoliflodacin/NUZOLVENCE).

• What is NUZOLVENCE (zoliflodacin)?
  

  NUZOLVENCE is described by Innoviva Specialty Therapeutics as a first-in-class, single-dose, oral antibiotic for the treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years and older weighing at least 35 kg. It is a spiropyrimidinetrione bacterial type II topoisomerase inhibitor with a mechanism of action distinct from currently approved antibiotics and demonstrated activity against drug-resistant Neisseria gonorrhoeae.

• What are the key safety considerations for NUZOLVENCE?
  

  Based on Innoviva’s published safety information, NUZOLVENCE carries warnings related to embryo-fetal toxicity, potential risks to male fertility and early pregnancy loss in partners, hypersensitivity reactions, Clostridioides difficile infection, and development of drug-resistant bacteria. The most common adverse reactions include headache, dizziness, nausea, and diarrhea.

• What is ZEVTERA (ceftobiprole) used for?
  

  ZEVTERA is an advanced-generation cephalosporin antibiotic indicated in the U.S. for adult patients with Staphylococcus aureus bloodstream infections (bacteremia), including right-sided infective endocarditis, adult patients with acute bacterial skin and skin structure infections, and adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia caused by susceptible organisms.

• How is Innoviva connected to GSK respiratory products?
  

  Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, as described in the company’s public statements.

• Does Innoviva invest in other healthcare companies?
  

  Yes. Innoviva reports a portfolio of strategic healthcare assets held through subsidiaries, including equity and long-term investments and term loans in companies developing therapies and technologies in areas such as infectious disease and neurological or psychiatric conditions.

• Where is Innoviva’s stock listed and what is its symbol?
  

  Innoviva’s common stock is registered under Section 12(b) of the Securities Exchange Act and trades on the NASDAQ Global Select Market under the ticker symbol INVA, as noted in its SEC filings.